公开(公告)号：CA2604356A1

公开(公告)日：2006-10-19

申请号：CA2604356

申请日：2006-04-11

Applicant: SOLVAY PHARM GMBH

Inventor： BRUECKNER REINHARD ,  MLINARIC MICHAEL ,  MOLONEY BRIAN ,  BOECKER CHRISTIANE ,  FISCHER YVAN ,  MARRISON LESTER ,  ZIEGLER DIETER ,  WITTE KLAUS ,  WESKE MICHAEL

IPC: C07D311/68 ,  A61K31/353 ,  A61K31/4025 ,  A61K31/453 ,  A61K31/497 ,  A61K31/5355 ,  A61P9/00 ,  C07D405/12 ,  C07D413/12

Abstract: Cardiovascular active compounds of the general formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process are described. Furthermore, pharmaceutical compositions comprising the compounds of Formula (I) are specified.

公开(公告)号：NO20061821L

公开(公告)日：2006-06-22

申请号：NO20061821

申请日：2006-04-25

Applicant: SOLVAY PHARM GMBH

Inventor： TURSKI LECHOSLAW ,  ZIEGLER DIETER ,  MESSINGER JOSEF ,  WESKE MICHAEL ,  PAHL AXEL ,  HOELTJE DAGMAR ,  FISCHER YVAN ,  MICHAELIS KATHRIN ,  KARIMI-NEJAD YASMIN ,  HOEFER CONSTANZE ,  IKONOMIDOU HRISSANTHI

IPC: C07K5/06 ,  A61K38/00 ,  A61K38/05 ,  A61P9/12 ,  C07K5/02 ,  C07K5/078

Abstract: Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R , R , R and R have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.

公开(公告)号：AR046106A1

公开(公告)日：2005-11-23

申请号：ARP040103705

申请日：2004-10-13

Applicant: SOLVAY PHARM GMBH

Inventor： SYKES DAVID ,  MOLONEY BRIAN ,  MARRISON LESTER ,  ZIEGLER DIETER ,  MLINARIK MICHAEL ,  BOCKER CHRISTIANE ,  BRUCKNER REINHARD ,  WESKE MICHAEL ,  WITTE KLAUS ,  FISCHER IVAN

IPC: A61K31/353 ,  C07D311/68 ,  C07D407/12 ,  A61K31/352 ,  A61P9/06

Abstract: Reivindicación 1: Compuesto de la fórmula general (1), en donde: R1 significa alquilo C1-4; R2 significa alquilo C1-4; R3 significa fenilo, que está eventualmente sustituido, 1-2 veces, con halógeno, alquilo C1-4, alcoxi C1-4 o trifluorometilo; naftilo o bifenilo; R4 significa hidrógeno; alquilo C1-6 o cicloalquil(C3-7)alquilo(C1-4); R5 significa hidrógeno; y R6 significa alquilo C1-6; fenil-alquilo(C1-4), cuyo grupo fenilo está eventualmente sustituido 1 vez con halógeno; furil-alquilo(C1- 4) o tetrahidronaftilo; o R5 y R6, junto con el nitrógeno al que están unidos, forman un anillo de piperazina sin sustituir el cual está eventualmente sustituido con fenilo.

公开(公告)号：CA2542813A1

公开(公告)日：2005-04-28

申请号：CA2542813

申请日：2004-10-14

Applicant: SOLVAY PHARM GMBH

Inventor： BOECKER CHRISTIANE ,  BRUECKNER REINHARD ,  MLINARIC MICHAEL ,  ZIEGLER DIETER ,  MARRISON LESTER ,  MOLONEY BRIAN ,  WESKE MICHAEL ,  SYKES DAVID ,  WITTE KLAUS ,  FISCHER YVAN

IPC: C07D311/70 ,  A61K31/353 ,  A61P9/00 ,  A61P37/00 ,  C07D311/68 ,  C07D407/12

Abstract: The invention relates to compounds of general formula (I), wherein the meani ng of R1, R2, R3, R4, R5 and R6 is given in a description, to a method for producing said compounds and to intermediate products thereof. Drugs containing the inventive compounds of formula (1) are also disclosed.

公开(公告)号：PL363518A1

公开(公告)日：2004-11-29

申请号：PL36351801

申请日：2001-07-12

Applicant: SOLVAY PHARM GMBH

Inventor： HEBEBRAND JOHANNES ,  ANTEL JOCHEN ,  PREUSCHOFF ULF ,  DAVID SAMUEL ,  SANN HOLGER ,  WESKE MICHAEL

IPC: G01N33/50 ,  A61K45/00 ,  A61P1/00 ,  A61P3/04 ,  C12Q1/02 ,  C12Q1/527 ,  G01N33/15

Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.

公开(公告)号：AT278441T

公开(公告)日：2004-10-15

申请号：AT01955345

申请日：2001-07-12

Applicant: SOLVAY PHARM GMBH

Inventor： HEBEBRAND JOHANNES ,  ANTEL JOCHEN ,  PREUSCHOFF ULF ,  DAVID SAMUEL ,  SANN HOLGER ,  WESKE MICHAEL

IPC: G01N33/50 ,  A61K45/00 ,  A61P1/00 ,  A61P3/04 ,  C12Q1/02 ,  C12Q1/527 ,  G01N33/15

Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.

公开(公告)号：HU0400988A2

公开(公告)日：2004-08-30

申请号：HU0400988

申请日：2002-05-14

Applicant: SOLVAY PHARM GMBH

Inventor： BERGER CLAUDIA ,  FISCHER YVAN ,  HOELTJE DAGMAR ,  WALDECK HARALD ,  WESKE MICHAEL ,  ZIEGLER DIETER

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/444 ,  A61K31/55 ,  A61K31/675 ,  A61K45/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P25/04 ,  A61P35/00 ,  A61P43/00 ,  C07D223/16

公开(公告)号：SK14102003A3

公开(公告)日：2004-08-03

申请号：SK14102003

申请日：2002-05-14

Applicant: SOLVAY PHARM GMBH

Inventor： BERGER CLAUDIA ,  FISCHER YVAN ,  HOLTJE DAGMAR ,  WALDECK HARALD ,  WESKE MICHAEL ,  ZIEGLER DIETER

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/444 ,  A61K31/55 ,  A61K31/675 ,  A61K45/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P25/04 ,  A61P35/00 ,  A61P43/00 ,  C07D223/16

公开(公告)号：HU0302309A2

公开(公告)日：2003-11-28

申请号：HU0302309

申请日：2001-07-12

Applicant: SOLVAY PHARM GMBH

Inventor： ANTEL JOCHEN ,  DAVID SAMUEL ,  HEBEBRAND JOHANNES ,  PREUSCHOFF ULF DR ,  SANN HOLGER ,  WESKE MICHAEL

IPC: G01N33/50 ,  A61K45/00 ,  A61P1/00 ,  A61P3/04 ,  C12Q1/02 ,  C12Q1/527 ,  G01N33/15

Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.

公开(公告)号：CZ2003156A3

公开(公告)日：2003-06-18

申请号：CZ2003156

申请日：2001-07-12

Applicant: SOLVAY PHARM GMBH

Inventor： HEBEBRAND JOHANNES ,  ANTEL JOCHEN ,  PREUSCHOFF ULF ,  DAVID SAMUEL ,  SANN HOLGER ,  WESKE MICHAEL

IPC: G01N33/50 ,  A61K45/00 ,  A61P1/00 ,  A61P3/04 ,  C12Q1/02 ,  C12Q1/527 ,  G01N33/15 ,  A61P3/00

Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.